Outcome of childhood B-cell acute lymphoblastic leukemia treated with SCMC-ALL-2005 protocol

  • JIANG Jian ,
  • ZHONG Ren ,
  • LU Yuan ,
  • TANG Jingyan ,
  • YUAN Xiaojun ,
  • WANG Ningling ,
  • XU Huijuan ,
  • LI Xuerong ,
  • JIANG Hui ,
  • SUN Lirong
Expand
  • 1.Department of Pediatrics, The Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong, China; 2.Department of Hematology/Oncology, Shanghai Children’s Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200127, China; 3.Department of Hematology, Shanghai Children’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200040, China; 4.Department of Hematology/Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; 5.Department of Pediatrics, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui, China

Received date: 2014-11-15

  Online published: 2014-11-15

Abstract

Objective To analyze the outcome of childhood B-cell acute lymphoblastic leukemia treated(ALL) with SCMC-ALL-2005 protocol. Methods Newly diagnosed B-cell ALL from May 1, 2005 to April 30, 2009 in five hospitals were treated and followed up according to SCMC-ALL-2005 protocol. Results A total of 601 cases with newly diagnosed B-cell ALL were enrolled. Among them, 539 cases (89.68%) were followed up until September 30, 2011. In 601 patients, there were 284 low-risk cases (LR group), 231 moderate-risk cases (MR group) and 86 high-risk cases (HR group) which were treated with SCMC-ALL-2005 protocol. The total complete remission rate during the period of induction was 98.84% and 7 cases did not achieve complete remission. The median time of the first event occurring was 35 months (2.94 years). Among 539 cases completing follow-up, 403 cases (74.77%) completed treatment including 223 cases (86.43%) in LR group, 150 cases (73.17%) in MR group and 30 cases (39.47%) in HR group. The rate of cases completing treatment was significantly different among three groups (P=0.001). The completion rate was highest in LR group and lowest in HR group. The 3-year overall survival (OS) rate was (83.3±1.8) %, and the 3-year EFS (event-free survival) rate was (79.2±1.9) % using a Kaplan-Meier method. The 5-year OS rate was (79.5±3.3) %, and the 5-year EFS rate was (70.9±3.7) %. There were significant differences in 3-year EFS rate and 5-year EFS rate among three groups (P<0.05). Conclusions Childhood B-ALL treated with SCMC-ALL-2005 protocol achieved a better therapeutic effect and prognosis. The multi-center collaborative research is useful for the standard treatment of ALL.

Cite this article

JIANG Jian , ZHONG Ren , LU Yuan , TANG Jingyan , YUAN Xiaojun , WANG Ningling , XU Huijuan , LI Xuerong , JIANG Hui , SUN Lirong . Outcome of childhood B-cell acute lymphoblastic leukemia treated with SCMC-ALL-2005 protocol[J]. Journal of Clinical Pediatrics, 2014 , 32(11) : 1028 . DOI: 10.3969 j.issn.1000-3606.2014.11.008

Outlines

/